Ετικέτες

Παρασκευή 9 Ιουνίου 2017

Adiponectin: its role in obesity-associated colon and prostate cancers

Publication date: Available online 9 June 2017
Source:Critical Reviews in Oncology/Hematology
Author(s): Santoshi Muppala, Siva KP Konduru, Neha Merchant, Judy Ramsoondar, Carlos Karan Rampersad, Balney Rajitha, Vidya Mukund, Jyothsna Kancherla, Anthea Hammond, Tapan Kumar Barik, Mastan Mannarapu, Afroz Alam, Riyaz Basha, Pallavula Veera Bramhachari, Dheeraj Verma, Pinninti Santosh Sushma, Subasini Pattnaik, Ganji Purnachandra Nagaraju
Adipose tissue synthesizes many proteins and hormones collectively called adipokines, which are linked to a number of diseases, including cancer. Low levels of adiponectin are reported to be a risk factor for obesity-related cancers including colorectal and prostate cancers. Accordingly, obesity/lifestyle-related diseases, including certain cancers, may be treated by developing drugs that act specifically on adiponectin levels in circulation. Adiponectin may also serve as a clinical biomarker in obesity-related diseases. Adiponectin-based therapies are known to inhibit cancer advancement and thus may provide a therapeutic approach to delay cancer progression. Better understanding of the function of adiponectin is of great significance in the fight against cancer. This timely review is concentrated on the role of adiponectin and the impact of obesity on the development of cancers, especially colorectal and prostate cancers.



http://ift.tt/2rb5QVL

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αναζήτηση αυτού του ιστολογίου